公开(公告)号：EP3285811A1

公开(公告)日：2018-02-28

申请号：EP16721697

申请日：2016-04-21

申请人： ROUSSY INST GUSTAVE

发明人： PIROZHKOVA IRYNA ,  OGRYZKO VASILY

IPC分类号： A61K48/00 ,  A61K31/7088 ,  C07K14/47 ,  C12N15/113 ,  C12N15/86

CPC分类号： A61K31/7088 ,  A61K48/00 ,  C07K14/4705 ,  C12N15/113 ,  C12N15/86 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2330/50 ,  C12N2740/16043

摘要： The present invention relates to products and compositions as well as their therapeutic uses in human or veterinary medicine. In particular, the invention provides ZNF555 as a new therapeutic target for the prevention or treatment of a musculoskeletal disease in a subject. Particular embodiments include wherein the musculoskeletal disease is selected from Facioscapulohumeral Dystrophy (FSHD), a myopathy, musculoskeletal fibromatosis and muscular cachexia. Also disclosed is a method for identifying and selecting a compound inhibiting or decreasing the expression or activity of ZNF555, the method comprising a step of detecting and/or measuring the level of expression of ZNF555 or ANTI in a muscle cell in the presence of a test compound, wherein an absent or decreased expression of ZNF555 or ANTI in comparison with a control muscle cell that has not been exposed to or contacted with the test compound, is indicative of the capacity of said compound to inhibit or decrease the expression or activity of ZNF555 in said cell.